Study: Use of PET and PET/CT is cost-effective for some cancers

03/31/2010 | HealthImaging.com

German researchers who examined data from Germany, Britain, other European countries and the U.S. found that on a patient basis, the costs for PET and PET/CT procedures are decreasing with the increase in use of the procedures for certain cancers, including nonsmall-cell lung cancer, Hodgkin's disease, non-Hodgkin's lymphoma and colorectal carcinoma. There still is a need for larger trials to determine the cost-effectiveness of the tests for other cancers, the researchers said.

View Full Article in:

HealthImaging.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA